Recent Quotes

My Watchlist

Indicators

Catalent Inc (NY: CTLT )

58.73 +0.13 (+0.22%)

Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,704,243
Open	58.51
Bid (Size)	58.09 (1)
Ask (Size)	58.90 (2)
Prev. Close	58.60
Today's Range	58.50 - 58.83
52wk Range	32.38 - 61.20
Shares Outstanding	170,341,553
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings

October 21, 2024

From Catalent, Inc.

Via Business Wire

Performance

YTD	+30.37%	+30.37%
1 Month	-3.26%	-3.26%
3 Month	-0.71%	-0.71%
6 Month	+4.19%	+4.19%
1 Year	+66.52%	+66.52%

More News

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent

October 18, 2024

Via Benzinga

Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival

October 15, 2024

Via Benzinga

Beyond The Numbers: 6 Analysts Discuss Catalent Stock

April 04, 2024

Via Benzinga

Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility

October 14, 2024

From Catalent, Inc.

Via Business Wire

FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears

October 10, 2024

Via Benzinga

Four Stocks To Watch This Week - Tuesday, Oct. 01

October 01, 2024

Via Talk Markets

Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

September 16, 2024

Via Investor's Business Daily

Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results

August 29, 2024

From Catalent, Inc.

Via Business Wire

Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater

August 16, 2024

Via The Motley Fool

Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany

July 16, 2024

From Catalent, Inc.

Via Business Wire

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty

June 21, 2024

Via Benzinga

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

June 01, 2024

Via Investor's Business Daily

Catalent Stockholders Approve Transaction with Novo Holdings

May 29, 2024

From Catalent, Inc.

Via Business Wire

Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?

May 28, 2024

Via The Motley Fool

Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI

May 24, 2024

Via Benzinga

CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024

May 09, 2024

Via InvestorPlace

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

May 08, 2024

From Catalent, Inc.

Via Business Wire

Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition

May 02, 2024

Via Benzinga

Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)

April 17, 2024

From Robbins LLP

Via Business Wire

Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating

April 12, 2024

Via Benzinga

Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings

April 10, 2024

From Robbins LLP

Via GlobeNewswire

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

March 26, 2024

Via The Motley Fool

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities

March 23, 2024

Via Talk Markets

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.